Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Study of Anti-HIV Therapy Intensification
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe.
- Trial name
- NCT00034086
- Testing
- Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections are leading causes of early death in patients who initiate antiretroviral therapy (ART) with advanced immunodeficiency.
- Trial name
- STATIS (NCT02057796)
- Testing
- Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, ART (Atripla, Truvada, Efavirenz, Combivir), Rifampin, isoniazid, pyrazinamide, ethambutol
- Where
- 4 sites in Cambodia, Côte d’Ivoire and 2 more
- Volunteers
- 1,050 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients
Actual update to the US Department of Health and Human Services treatment guidelines for HIV-1 infection and European AIDS Clinical Society guidelines indicate Dovato(Dolutegravir/lamivudine) as an initial treatment in HIV-naÏve…
- Trial name
- NCT05332470
- Testing
- Lamivudine and Dotiravir Sodium Tablets
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
HIV-1
Fuzeon Viral Decay Pilot Study
In order to better understand the source(s) and the mechanism(s) of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs, we propose to examine the effect of co-administration of…
- Trial name
- NCT00334022
- Testing
- enfuvirtide
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infection
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic…
- Trial name
- NCT04340596
- Testing
- N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
- Where
- 14 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ART Adherence, HIV-1-infection
Call for Life Youth ART Adherence Study
Study purpose: To assess effect of mHealth Call for life Uganda tool (CFLU) on ART adherence among youth measured by interactive voice response to daily adherence calls mapped in the database and proportion with viral suppression…
- Conditions
- ART Adherence, HIV-1-infection, mHealth
- Trial name
- C4L-Youth (NCT04718974)
- Testing
- mHealth call for life system/ tool using IVR ( interactive voice response)
- Where
- Uganda
- Volunteers
- 206 people
- Sponsor
- Makerere University
HIV-1 Infection
Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients
This is a multi-center prospective study. The primary objective of DRONE study is to investigate the change of the size of HIV-1 DNA reservoir in blood from baseline to week 48 (W48) in participants treated by DTG-based regimen.
- Trial name
- DRONE (NCT02370979)
- Testing
- Blood samples
- Where
- 4 sites in France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Strasbourg, France
HIV Infections, HIV Seronegativity
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to see if the experimental vaccine, ALVAC-HIV (vCP1452) is safe and to study how the immune system responds to the vaccine.
- Trial name
- NCT00027261
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 13 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).
- Trial name
- BIC-STaR (NCT03580668)
- Testing
- B/F/TAF
- Where
- 6 sites in Canada
- Volunteers
- 201 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
The purpose of this phase II study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.
- Trial name
- NCT02369146
- Testing
- UB-421
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- United BioPharma
HIV Infection
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
The objectives of this Phase I/II trial is to evaluate the safety, tolerability and immunogenicity of THV01 compared to placebo in HIV-1 infected patients on HAART (highly active antiretroviral therapies).
- Trial name
- NCT02054286
- Testing
- THV01-1, THV01-2
- Where
- 11 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Theravectys S.A.
HIV-1-infection
Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected
The objective of this study is to explore the impact of initiation of ART with different regimens in naïve MSM (in the setting of acute and chronic HIV-infection) on the probability of transmission of HIV by mathematical modeling.
- Trial name
- MIAMI (NCT03183154)
- Testing
- no intervention
- Where
- Spain
- Volunteers
- 1,831 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
HIV Infections
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).
- Trial name
- NCT00011895
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
- Where
- 42 sites in United States
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in…
- Trial name
- NCT02016924
- Testing
- ATV, DRV, Cobicistat
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 133 people
- Sponsor
- Gilead Sciences
HIV Infection
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-HAV vaccine in HIV-1 infected patients with CD4…
- Trial name
- HEPAVAC (NCT00190242)
- Testing
- group1, group2
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections
A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.
- Trial name
- NCT00002354
- Testing
- Indinavir sulfate, Stavudine
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
Genotype-Informed Versus Empiric Management of VirEmia
HIV infection can be effectively controlled with antiretroviral therapy (ART). However, children and adolescents living with HIV and receiving ART suffer high rates of treatment failure, predominantly caused by suboptimal…
- Trial name
- GIVE MOVE (NCT04233242)
- Testing
- Clinical management informed by HIV-1 genotypic resistance testing
- Where
- 10 sites in Lesotho, Tanzania
- Volunteers
- 286 people
- Sponsor
- Swiss Tropical & Public Health Institute
HIV Infections
Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART
A cross-sectional study was performed on HIV-1 infected individuals with or without antiretroviral treatment. 73 HIV-1 infected individuals were divided into three groups: G1= 15 infected individuals with or without AIDS who…
- Trial name
- NCT00746473
- Where
- Brazil
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV-1 Infection
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
This is a non-inferiority (10% non-inferiority margin), study to assess the efficacy and safety of dolutegravir, DTG (50 mg once daily [QD]) administered in combination with tenofovir alafenamide fumarate, TAF (25 mg QD) and…
- Trial name
- ADVANCE (NCT03122262)
- Testing
- Dolutegravir, Tenofovir Alafenamide, Truvada
- Where
- 4 sites in South Africa
- Volunteers
- 1,110 people
- Sponsor
- Professor Francois Venter
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.